We don't prescribe statins to lower cholesterol: We prescribe statins to reduce vascular risk

Journal of the American Society of Nephrology

Volumn 26, Issue 5, 2015, Pages 1001-1003

  Tonelli, Marcello ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EDITORIAL; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HEART INFARCTION; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; COMPLICATION; FEMALE; MALE;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84929340611     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014090952     Document Type: Editorial

References (9)

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681, 2010
2. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, James M, Hemmelgarn B; Alberta Kidney Disease Network: Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 24: 979-986, 2013
3. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network: Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet 380: 807-814, 2012
4. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members: Lipid management in chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 160: 182, 2014
5. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129[Suppl 2]: S1-S45, 2014
6. Colantonio LD, Baber U, Banach M, Tanner RM, Warnock DG, Gutiérrez OM, Safford MM, Christoph W, Howard G, Muntner P: Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol 26: 1173-1180, 2015
7. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37: 484-489, 2001
8. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282: 1458-1465, 1999
9. Murray CJ, Lopez AD: Measuring the global burden of disease. N Engl J Med 369: 448-457, 2013